| 236.63 Delayed Data As of Sep 13 |  +4.32 / +1.86%Today’s Change | 215.78 Today|||52-Week Range 358.41 | -21.36% Year-to-Date |
| What September Doldrums? Here's Why Stocks Are Moving Higher Sep 13 / Zacks.com - Paid Partner Content | 5 Price-to-Book Value Picks for September Sep 05 / Zacks.com - Paid Partner Content |
| Top 5 ROE Stocks to Profit as Sino-US Trade Tensions Abate Sep 13 / Zacks.com - Paid Partner Content | Novartis Inks Commercialization Deal for Tysabri Biosimilar Sep 04 / Zacks.com - Paid Partner Content |
| Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group Sep 09 / Zacks.com - Paid Partner Content |
| Previous close | 232.31 |
| Today’s open | 232.00 |
| Day’s range | 232.00 - 237.98 |
| Volume | 1,688,983 |
| Average volume (3 months) | 1,516,797 |
| Market cap | $43.6B |
| Earnings growth (last year) | +81.10% |
| Earnings growth (this year) | +23.05% |
| Earnings growth (next 5 years) | +5.00% |
| Revenue growth (last year) | +9.67% |
| P/E ratio | 8.8 |
| Price/Sales | 5.13 |
| Price/Book | 3.58 |
| Today’s change | Today’s % change | |
|---|---|---|
| ILMNIllumina Inc | +3.39 | +1.14% |
| EXASExact Sciences Corp | -1.98 | -1.82% |
| BMRNBiomarin Pharmaceuti... | -0.15 | -0.21% |
| NBIXNeurocrine Bioscienc... | +2.28 | +2.42% |
| Next reporting date | October 22, 2019 |
| EPS forecast (this quarter) | $8.23 |
| Annual revenue (last year) | $12.1B |
| Annual profit (last year) | $4.4B |
| Net profit margin | 36.76% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Michel Vounatsos |
Chief Financial Officer & Executive Vice President Jeffrey D. Capello |
Corporate headquarters Cambridge, Massachusetts |
